These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35850432)

  • 1. Repurposing of parenterally administered active substances used to treat pain both systemically and locally.
    Battaglia LS; Dorati R; Maestrelli F; Conti B; Gabriele M; Di Cesare Mannelli L; Selmin F; Cosco D
    Drug Discov Today; 2022 Oct; 27(10):103321. PubMed ID: 35850432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
    Constantinides PP; Chaubal MV; Shorr R
    Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments.
    Wang Y; Grainger DW
    Adv Drug Deliv Rev; 2019; 151-152():56-71. PubMed ID: 30898571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Recent Update on Drug Delivery Systems for Pain Management.
    Phadke A; Amin P
    J Pain Palliat Care Pharmacother; 2021 Sep; 35(3):175-214. PubMed ID: 34157247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supercritical fluid (SCF)-assisted fabrication of carrier-free drugs: An eco-friendly welcome to active pharmaceutical ingredients (APIs).
    Kankala RK; Xu PY; Chen BQ; Wang SB; Chen AZ
    Adv Drug Deliv Rev; 2021 Sep; 176():113846. PubMed ID: 34197896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory pitfalls and opportunities when repurposing for inhalation therapy.
    Lyapustina S
    Adv Drug Deliv Rev; 2018 Aug; 133():57-65. PubMed ID: 29679606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
    Jenke D; Carlson T
    PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influencing Factors of the Pharmacokinetic Characters on Nanopharmaceutics.
    Ji X; Lu W; Wu K; Cho WC
    Pharm Nanotechnol; 2017; 5(1):24-31. PubMed ID: 28948908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.
    Sudhakar Y; Kuotsu K; Bandyopadhyay AK
    J Control Release; 2006 Aug; 114(1):15-40. PubMed ID: 16828915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing drug molecules for new pulmonary therapeutic interventions.
    Mehta PP; Dhapte-Pawar VS
    Drug Deliv Transl Res; 2021 Oct; 11(5):1829-1848. PubMed ID: 33188495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation strategies and particle engineering technologies for pulmonary delivery of biopharmaceuticals.
    Cun D; Wan F; Yang M
    Curr Pharm Des; 2015; 21(19):2599-610. PubMed ID: 25876915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nano-based drug delivery system enhances the oral absorption of lipophilic drugs with extensive presystemic metabolism.
    Zhang Z; Gao F; Jiang S; Ma L; Li Y
    Curr Drug Metab; 2012 Oct; 13(8):1110-8. PubMed ID: 22380010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How nano-engineered delivery systems can help marketed and repurposed drugs in Alzheimer's disease treatment?
    Séguy L; Groo AC; Malzert-Fréon A
    Drug Discov Today; 2022 Jun; 27(6):1575-1589. PubMed ID: 35227886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical structure modifications and nano-technology applications for improving ADME-Tox properties, a review.
    Farouk F; Shamma R
    Arch Pharm (Weinheim); 2019 Feb; 352(2):e1800213. PubMed ID: 30609117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCS class IV drugs: Highly notorious candidates for formulation development.
    Ghadi R; Dand N
    J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of innovative technologies to the delivery of antipsychotics.
    Bergonzi MC; Bilia AR; Landucci E
    Drug Discov Today; 2022 Feb; 27(2):401-421. PubMed ID: 34601123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel analgesics through a drug repurposing strategy.
    Gazerani P
    Pain Manag; 2019 Jul; 9(4):399-415. PubMed ID: 30950770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach.
    Hamidi M; Azadi A; Rafiei P; Ashrafi H
    Crit Rev Ther Drug Carrier Syst; 2013; 30(5):435-67. PubMed ID: 24099328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing and advancing dry powder inhalation towards enhanced therapeutics.
    Stegemann S; Kopp S; Borchard G; Shah VP; Senel S; Dubey R; Urbanetz N; Cittero M; Schoubben A; Hippchen C; Cade D; Fuglsang A; Morais J; Borgström L; Farshi F; Seyfang KH; Hermann R; van de Putte A; Klebovich I; Hincal A
    Eur J Pharm Sci; 2013 Jan; 48(1-2):181-94. PubMed ID: 23142635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.